NewsBenzinga摩根大通维持对 Cytokinetics 的“增持”评级,将目标价下调至 100 美元 摩根大通维持对 Cytokinetics 的“增持”评级,将目标价下调至 100 美元 Benzinga 2026.11.20 17:52 (GMT+0) Open on Benzinga Other news UBS Maintains Buy on Keysight Techs, Lowers Price Target to $380 UBS Maintains Neutral on Intuit, Lowers Price Target to $315 Walmart Gets Bullish Rating Despite Pharmacy Deflation Headwinds Sky's USDC Exit Reserve Rises 29% to 1.13 Billion UBS Maintains Neutral on Ingredion, Lowers Price Target to $98 UBS Maintains Neutral on Hewlett Packard, Lowers Price Target to $52